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Objective: To evaluate the anti-obesity activity of bixin (BIX) on C57BL/6J mice which
were fed a high-fat diet (HFD) and to determine the mechanism of this effect.
Methods: C57BL/6J mice were separately fed a high-calorie diet or a normal diet for 8
weeks, then they were treated with BIX for another 13 weeks. After administration for 13
weeks, the animals were sacriﬁced. Body adiposity, serum lipid level, and insulin
resistance were evaluated. In addition, a histological assay of pancreas and liver, an
evaluation of the inhibitory properties on pancreatic lipase, and a-amylase were
conducted.
Results: Administration of BIX signiﬁcantly decreased the body weight gain, adipocyte
size, fat pad weights, hepatic lipid levels in HFD-induced obese mice. In addition,
reduced liver weight exhibited decreased serum leptin levels, malic enzyme, glucose-6-
phosphate dehydrogenase, hepatic fatty acid synthase, aspartate aminotransferase,
alanine aminotransferase and hepatic phosphatidate phosphohydrolase activity. However,
superoxide dismutase, catalase, glutathione peroxidase, and glutathione levels were
increased in hepatic tissue. BIX also decreased lipid and carbohydrates absorption due to
inhibition of pancreatic lipase and a-amylase. Long term supplementation of BIX
signiﬁcantly decreased hyperlipidemia, insulin resistance and glucose level. Decreased
levels of hepatic steatosis and the islets of Langerhans appeared less shrunken in HFD-fed
mice.
Conclusions: The antiobesity effect of BIX appears to be associated at least in part, to its
inhibitory effect on lipids and carbohydrate digestion enzymes such as pancreatic lipase,
a-glucosidase, and a-amylase. The results suggested that BIX also act as an antioxidant
and may treat visceral obesity normalizing glucose levels, improving insulin resistance
and increasing energy expenditure. Therefore, achiote which has a main component, the
carotenoid BIX, could be a viable food for the treatment of obesity and diabetes.1. Introduction
Obesity is a disorder of the metabolism of carbohydrates and
fats resulting in an excessive fat deposition in adipose tissue andother organs [1]. Imbalance in energy causes obesity and visceral
adiposity increasing production of reactive oxygen species
(ROS) that predisposes individuals to complications such as
oxidative stress, metabolic disturbances, insulin resistance, and
lipogenesis. The adipose tissue is an endocrine organ that
secretes some adipokines such as tumor necrosis factor-a
(TNF-a), leptin, interleukin-6 (IL-6), chemoattractant proteins
like chemokine (C–C motif) ligand-2, proteins and C–C che-
mokine receptor 2, plasminogen activator inhibitor-I [2].
Numerous enzymes such as pancreatic lipase, a-amylase and
a-glucosidase are involved in lipid and carbohydrate metabolic
pathways, representing therapeutic targets for obesity [3].
Currently, available anti-obesity agents have a modest efﬁcacy
and undesirable side effects. This is why new antiobesity drugs
have been looked for in natural sources that may have minimal
side effects and reduce body weight.article under the CC BY-NC-ND license (http://
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cooking in South America and Mexico. Bixa orellana seed coat
contains apocarotenoids [4]. Bixin (BIX) reduces inﬂammatory
response [5], improves lipid proﬁles, has antihyperglycemic
activity, and protects from oxidative stress in diabetic rats [6].
Treatment with BIX enhances anti-adipogenic effect in 3T3-L1
adipocytes by regulating peroxisome proliferator-activated recep-
tor alpha [7,8]. This study examined the effect of oral administration
of BIX on obesity related biochemical parameters, weight loss,
adipogenesis and metabolism changes in liver dysfunction,
hepatic steatosis and oxidative stress in C57BL/6J mice.
2. Materials and methods
2.1. Mouse model of diet-induced obesity
Adult male C57BL/6J mice, (60 days, weighing 20–25 g)
were provided by the bioterio of the National School of Bio-
logical Sciences of the National Polytechnic Institute. Mice were
adapted under controlled conditions [12 h light/dark cycle and
temperature (23 ± 2) C] for a week. Subsequently, 105 mice
were randomly divided into ﬁfteen groups with seven mice per
group. The experimental protocol used throughout the research
followed the statutes for animal experimentation indicated by the
Laboratory Animal Care (National Institute of Health publica-
tion 85-23), and Mexican Ofﬁcial Normativity (NOM-062-Z00-
1999). Finally, all experiments were approved by committee of
the use and handling of laboratory animals (permission number
756/lab/ENCB-IPN).
2.2. Supplementation of BIX
The C57BL/6J mice were individually housed in standard
cages. The high-fat-diet (HFD) consisted of 24% corn oil, 6%
sugar, 20% full-cream milk powder in 50% normal rat chow
pellet [9]. All mice were fed experimental diet (HFD) ad libitum
and with free access to water during the 8 weeks of the
experimental period. During the feeding period, food intake
and body weight were monitored daily and every 2 days
respectively [9]. After 8 weeks of feeding HFD, the resultant
obese mice were treated with BIX (Sigma–Aldrich, St. Louis,
MO, USA) at doses of 5 (BIX-5), and 10 mg/kg (BIX-10),
which were prepared dissolving the BIX in 1% Tween 80.
Then, this carotenoid was orally administered at a volume of
0.1 mL daily for 14 weeks. The normal mice and obese
control (HFD) groups were administered only 1% Tween 80,
using orlistat (Roche, DF, Mexico) as standard (5 mg/kg). The
administration of 5 mg/kg and 10 mg/kg of BIX was calculated
on basis of the amount of commercial orlistat.
2.3. Biochemical analysis
At Week 14 after starting supplementations period, mice were
sacriﬁced with diethyl ether to collect the retroperitoneal, epidid-
ymal, subcutaneous fat livers. Blood samples were collected from
vena cava for biochemical parameters determination. Blood was
centrifuged at 2000 r/min for 20 min at 4 C, and the plasma was
used for subsequent analyses. High density lipoprotein cholesterol
(HDL-C), total cholesterol, triglycerides (TG), plasma activities of
glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic
transaminase (GPT) were measured with commercial diagnostickit from Cayman Chemical Company (Ann Arbor, Michigan, MI,
USA). Low density lipoprotein cholesterol (LDL-C) was
measured using Friedewald equation [10]. The non-esteriﬁed fatty
acid levels were measured with free fatty acid (FFA) assay kit (Cat
No: 700310, Cayman Chemical). Aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) were calculated by
enzymatic assay kits (Wako Pure Chemical, Osaka, Japan). Adi-
ponectin and leptin were calculated using mouse ELISA kits
(R&D Systems, Minneapolis, MN, USA), performed with a
microplate spectrophotometer (Bio-Rad, Hercules, CA, USA).
The insulin level was estimated using an ELISA kit (INSMSU-
E01, ALPCO Diagnostics, Salem, NH, USA). The homeostasis
model assessment of insulin resistance (HOMA-IR) was calcu-
lated based on the following equation: HOMA-IR = Glucose
(nmol/L) × Insulin (mIU/mL)/22.5.
Hepatic TNF-a was determinated using a mouse TNF-a
ELISA kit (Millipore, Temecula, CA, USA). IL-1b and IL-6 were
estimated using enzymatic kits (eBioscience, Inc., San Diego,
CA). All samples were assayed in triplicate and procedures were
performed according to the manufacturer instructions.
2.4. Faecal lipids excretion
Faeces were collected in the last days of experiment. The
total amount of faeces was dried at 100 C during 4 days,
weighed and homogenized with twice the volume of water, and
then faecal lipids were extracted using the Folch extraction
method [11].
2.5. Lipid peroxidation (LPO) and xanthine oxidase
(XO) inhibition assay
The ability of BIX to inhibit LPO in mice liver homogenate
was determined by the formation of malondialdehyde (MDA)
equivalents calculated by the thiobarbituric acid reactive sub-
stances (TBARS) assay [12]. Liver homogenate was mixed with
20% (w/v) acetic acid (pH 3.5), 8.1% sodium dodecyl sulfate
and 0.8% (w/v) thiobarbituric acid. The reaction was heated for
60 min at 95 C. Then a pyridine n-butano (1:15, v/v) mixture
was added and centrifuged for 15 min at 3000 r/min then
measured at 535 nm. Ascorbic acid was used as positive control.
Measurement of scavenging ROS was assayed by the XO
assay kit (BioVision, USA) in liver homogenate.
2.6. Antioxidant effect of BIX on enzyme activity
Heme oxygenase 1 (HO-1) activity in liver and plasma was
estimated with the HO-1 Mouse SimpleStep ELISA kit (Empire
Genomics, Buffalo, NY, USA). Superoxide dismutase (SOD),
catalase (CAT), glutathione (GSH) reductase, and glutathione
peroxidase (GSH-Px) activities were estimated using commer-
cial kits. All the assay kits were purchased from Cayman
Chemical (MI, USA), and all procedures were performed with
the manufacturer instructions.
2.7. Effect of BIX on hepatic lipid regulating enzymes
Mitochondrial pellet was obtained from the liver [13]. Protein
concentration was estimated base on Bradford method [14] using
bovine serum albumin as standard. The fatty acid synthase
(FAS) activity was determined with an assay in which the
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nicotinamide adenine dinucleotide phosphate in mmol/L/min/mg
of protein [15]. Then enzymatic activity of glucose-6-phosphate
dehydrogenase (G6PD) and malic enzyme (ME) was calculated
with a commercial kit (Sigma–Aldrich, St. Louis, MO, USA). The
phosphatidate phosphohydrolase (PAP) activity was determined
using the method developed by Khokha et al. [16]. The a-
glucosidase, pancreatic lipase and a-amylase inhibitory activities
were evaluated with a speciﬁc assay kit (BioVision, CA, USA).
2.8. Histological analysis of liver and pancreas
Liver and pancreas were removed from the mice and ﬁxed in
a solution of formalin (10%). Then, tissues were embedded in
parafﬁn and immediately sectioned to obtain 4 mm thick sec-
tions. The steatosis was classiﬁed according to the method
described by Zelber-Sagi et al. [17]. Sections of the organs were
stained with hematoxylin and eosin dyes and examined with an
optical microscope (Nikon, Tokyo, Japan).
2.9. Statistical analysis
Each value was presented as the mean ± SD. One-way
ANOVA was used for multiple comparisons, followed by the
Tukey test with XLSTAT7.1 software, and a P value of less than
0.05 was considered statistical signiﬁcance.
3. Results
In this study, after 14 weeks of feeding a HFD to male C57BL/
6J mice, the body weight was signiﬁcantly increased (133%)
compared with that of the normal diet mice, indicating that HFD
produced obesity (Table 1). BIX was orally administered at 5 andTable 1
Effect of BIX on body weight, food intake, adipose tissue weight, fecal tota
Groups NC
Body weight (g) Initial body weight 21.00 ± 1.76
Final body weight 31.23 ± 1.26
Body weight gain (g/day) 10.23 ± 2.71
Food intake (g/mice/day) 2.65 ± 0.78
Adipose tissue (g/100 g
body weight)
Epididymal fat 1.19 ± 0.26
Retroperitoneal fat 0.90 ± 0.39
Subcutaneous fat 0.38 ± 0.15
Total fat 2.47 ± 0.75
Weight ratios kidney 1.69 ± 0.03
Fecal total lipids
(mg/g wet weight)
39.45 ± 5.72
NC: Normal diet control. Values are expressed as mean ± SD (n = 6). a: P
Table 2
Effect of BIX on hepatic lipid content, liver weight, hepatic TG, hepatic cho
Groups NC HFD
Weight ratios liver (g/100 g body weight) 5.51 ± 0.31 5.56 ± 0.35
FFA (mmol/g liver) 5.73 ± 1.45 23.84 ± 3.76
Hepatic TG (mg/g) 13.26 ± 3.19 48.65 ± 6.27
Hepatic cholesterol (mg/g) 5.72 ± 1.07 11.90 ± 3.45
AST (IU/L) 0.49 ± 0.03 0.77 ± 0.01
ALT (IU/L) 0.35 ± 0.04 0.84 ± 0.08
LPO (MDA nmol/mg protein) 0.86 ± 0.01 1.42 ± 0.57
Values are expressed as mean ± SD (n = 6). a: P < 0.05, b: P < 0.01, c: P10 mg/kg over a period of 14 weeks; in the end BIX decreased the
bodyweight ofmice by 17% and 47% respectively comparedwith
HFD control. During the last 14 weeks of experimentation, food
intake among the groups HFD and HFD-BIX did not differ. Also,
the weight of the retroperitoneal, subcutaneous, and epididymal
adipose tissues at the end of the experiment was signiﬁcantly
(P < 0.001) higher in the HFD group than in the NC group. Body
weight gain (g/day) produced by BIX-5 and BIX-10 mg/kg was
signiﬁcantly different when compared to HFD group. The weight
of kidney and liver was signiﬁcantly lower in the 5 and 10 mg/kg
BIX groups than those of the HFD group.
Fecal lipid excretion in the HFD group was signiﬁcantly
(P < 0.001) higher compared with the NC diet group after
14 weeks of treatment. BIX 5 and 10 mg/kg supplementation
increased fecal lipid excretion (50% and 56%, respectively) in
comparison with the HFD group. This may be partially due to
the decreased lipid absorption produced by inhibition of
pancreatic lipase enzyme. In addition, there were no signiﬁcant
differences among the faecal lipid levels in the experimental
groups (Table 1).
The weight of liver was signiﬁcantly higher in the HFD
supplemented mice compared to NC diet mice group. HFD mice
had elevated FFA (P < 0.001), TG (P < 0.001) and cholesterol
(P < 0.01) levels. BIX supplementation at dose of BIX-5 and
BIX-10 signiﬁcantly reduced liver weight (7% and 9%, respec-
tively), ALT (31% and 54% decrease, respectively) and AST
(21% and 31% decrease, respectively), FAS (50% and 57% in-
hibition, respectively), cholesterol (30% and 46% inhibition,
respectively), TG (52% and 60% inhibition, respectively), LDL-C
(29.59% and 43.33% inhibition, respectively) levels. However,
HDL-C level was diminished in hyperlipidemic mice (HFDmice)
and a signiﬁcant rise of HDL-C was observed in BIX treatment
mice. Data are presented in Table 2.l lipids and weight of kidney in HFD-fed obese mice.
HFD HFD + BIX-5 HFD + BIX-10 HFD + Orlistat
21.12 ± 2.13 20.92 ± 2.65 21.76 ± 2.65 21.24 ± 2.67
49.38 ± 3.26 40.17 ± 5.73a 35.31 ± 4.86a 39.77 ± 3.19c
28.26 ± 1.71 17.25 ± 1.34b 11.55 ± 0.34b 18.53 ± 2.04b
2.59 ± 1.59 2.53 ± 1.48 2.51 ± 1.32 2.50 ± 1.58
1.91 ± 0.34 1.62 ± 0.54 1.34 ± 0.68 1.58 ± 0.48
1.60 ± 0.65 1.37 ± 0.92c 1.01 ± 0.46c 1.33 ± 0.44c
1.82 ± 0.28 1.69 ± 0.92c 1.19 ± 0.17c 1.75 ± 0.50c
5.33 ± 0.75 4.68 ± 0.69a 3.54 ± 0.69a 4.66 ± 0.69b
1.44 ± 0.07 1.50 ± 0.04 1.55 ± 0.06 1.49 ± 0.05
77.36 ± 7.48 116.18 ± 8.96a 120.46 ± 8.52c 118.54 ± 9.03b
< 0.05, b: P < 0.01, c: P < 0.001, when compared to HFD group.
lesterol, hepatic antioxidant capacity in C57BL/6J obese mice.
HFD + BIX-5 HFD + BIX-10 HFD + Orlistat Ascorbic acid
5.67 ± 0.39c 5.86 ± 0.39c 3.57 ± 0.62c
8.19 ± 1.53c 6.32 ± 1.94b 9.31 ± 3.21c
23.52 ± 5.40b 19.21 ± 3.87a 28.39 ± 4.58b
8.34 ± 1.98a 6.43 ± 1.21b 8.78 ± 2.76a
0.61 ± 0.02c 0.53 ± 0.04c 0.69 ± 0.02
0.58 ± 0.08a 0.46 ± 0.02c 0.80 ± 0.02
0.88 ± 0.05b 0.85 ± 0.03a 1.49 ± 0.08 0.89 ± 0.07a
< 0.001, when compared to HFD group.
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it correlated with insulin resistance and adipose tissue mass. Serum
leptin level increased in group compared to NC-fed mice (Table 3).
BIX treated groups (HFD plus BIX-5 and BIX-10) exhibited
decreased serum leptin levels compared with the HFD group.Table 3
Effect of BIX on blood parameters after feeding for 14 weeks.
Groups NC HFD HFD + BIX-5 HFD + BIX-10 HFD + Orlistat Ascorbic acid
Glucose (mg/dL) 102.40 ± 5.89 178.10 ± 7.51b 112.40 ± 7.14a 102.30 ± 6.29c 177.10 ± 5.38
Insulin (ng/mL) 0.85 ± 0.04 100.34 ± 0.02b 0.57 ± 0.08a 0.52 ± 0.02c 0.94 ± 0.02c
HOMA-IR 6.16 ± 0.64 9.75 ± 0.70 4.12 ± 0.28c 4.02 ± 0.39c 9.47 ± 0.32 b
Cholesterol (mg/dL) 89.21 ± 5.71 210.38 ± 9.32a 138.21 ± 6.43a 123.25 ± 7.62b 123.11 ± 6.22a
TG (mg/dL) 131.45 ± 5.86 195.39 ± 8.20b 150.48 ± 3.98a 135.29 ± 4.18a 138.34 ± 3.64c
HDL-C (mg/dL) 41.72 ± 2.80 34.01 ± 4.39a 38.35 ± 5.06c 40.87 ± 4.88c 39.37 ± 2.45c
LDL-C (mg/dL) 22.76 ± 3.74 109.90 ± 5.64a 77.37 ± 4.19c 69.27 ± 6.36b 79.27 ± 6.36a
Atherogenic index 0.49 ± 0.06 0.75 ± 0.03 0.59 ± 0.09c 0.51 ± 0.07a 0.54 ± 0.05 b
GOT (Karmen/mL) 165.43 ± 8.39 205.21 ± 7.87 173.56 ± 6.38a 167.29 ± 7.87a 194.53 ± 9.39
GPT (Karmen/mL) 25.61 ± 4.73 128.19 ± 6.43 58.25 ± 5.28b 49.87 ± 5.29b 125.48 ± 7.17
AST (IU/L) 67.60 ± 8.29 77.60 ± 6.94 72.20 ± 7.16c 69.50 ± 9.38c 77.10 ± 7.19
ALT (IU/L) 35.60 ± 2.44 43.90 ± 1.76 28.40 ± 3.80a 25.70 ± 5.23c 23.10 ± 5.17
LPO (MDA mmol/L) 19.86 ± 4.61 31.28 ± 6.52 24.32 ± 5.73b 20.51 ± 4.73a 32.29 ± 3.88 21.34 ± 5.06a
Leptin (ng/mL) 4.16 ± 1.28 20.01 ± 5.74 10.92 ± 2.87a 8.23 ± 4.19a 20.62 ± 4.36
Adiponectin (mg/mL) 7.56 ± 3.21 6.12 ± 4.77 6.90 ± 4.19 7.24 ± 3.61a 6.16 ± 2.43
a: P < 0.05, b: P < 0.01, c: P < 0.001, when compared to HFD group.Metabolic parameters of the obese mice, including insulin
levels, glucose, cholesterol, TG, and LDL were signiﬁcantly
elevated by HFD (Table 3). However, HDL cholesterol level
was diminished in HFD group.
In this study, long term BIX supplementation signiﬁcantly
decreased hiperlipidemia, insulin resistance and glucose level in
HFD fed mice (Table 3).
To assess the effect of BIX-supplemented mice on hepatic
function, we measured the activity of enzymes GPT, GOT, AST
and ALT. These activities in BIX-5 and BIX-10 treated groups
were GOT (15% and 18% decrease, respectively), GPT (55%
and 61% decrease, respectively), AST (21% and 31% decrease,
respectively) and ALT (35% and 53% decrease, respectively).
BIX supplementation resulted in a signiﬁcant reduction in ac-
tivity of enzymes GPT, GOT, AST and ALT (Table 3).
The hepatic TBARS was a marker of lipid peroxide pro-
duction. Oxidative stress in the liver was calculated by
measuring the levels of LPO, and the activities of related en-Table 4
Effect of treatment with BIX on liver antioxidant enzyme activity in C57BL/6J obese mice.
Groups SOD (IU/min) CAT (IU/s) GSH-Px (IU/mL) GSH (IU/mL) HO-1 (pg/mL)
NC 6.60 ± 0.18a 0.730 ± 0.002b 99.35 ± 7.19a 47.32 ± 3.91b 2.27 ± 102
HFD 5.00 ± 0.23 0.620 ± 0.007 40.28 ± 4.38 25.13 ± 5.22 1.82 ± 103
BIX-5 5.60 ± 0.43 0.660 ± 0.009 76.54 ± 5.21b 36.78 ± 4.33a 1.53 ± 103
BIX-10 6.10 ± 0.42a 0.700 ± 0.006b 66.92 ± 5.89a 31.09 ± 4.80b 1.12 ± 103
Each value represents the mean ± SEM from 6 rats. a: P < 0.05 and b: P < 0.01 when compared to HFD group.zymes with the oxidative stress, including SOD, CAT, GSH-Px,
GSH, HO-1 and XO in liver homogenates. The concentration of
LPO was determined by the measuring of MDA, which was a
product of lipid breakdown caused by peroxidation damage.
Furthermore, liver MDA levels were elevated in the HFD-fed
group compared with the NC group. MDA levels weresigniﬁcantly decreased in the liver of the BIX-supplemented
mice (HFD + BIX-5 and HFD + BIX-10) and ascorbic acid
treatment (HFD + ascorbic acid) compared with the NC mice
(Table 3). Moreover, the result indicated a slight difference of
inhibition activity between BIX and ascorbic acid.Table 3 shows the effects of BIX on leptin and adiponectin.
Signiﬁcant increase in the levels of plasma of adiponectin was
observed in the HFD fed groups for 14 weeks. After treatment
with BIX, the plasma leptin was signiﬁcantly decreased compared
to leptin level in HFD-fed control groups. It also showed a sig-
niﬁcant reduction of leptin in the BIX-5 and BIX-10 treatment
groups (45.4% and 58.9%, respectively).
HFD induced oxidative stress and inﬂammation in the liver,
indicating the decline in the concentration of the antioxidant en-
zymes GSH, GSH-Px, SOD, CAT, HO-1 and XO (Table 4). BIX
supplementation elevated activities of these enzymes. The assess-
ment of antioxidant potential showed that the BIX possessed highly
inhibitory effects on the XO (IC50 = 15.6 mg/mL). Pro-inﬂamma-
tory cytokine levels of TNF-a, IL-1b and IL-6 were elevated in the
HFD group. However, cytokines IL-1b and IL-6 were not signiﬁ-
cantly different between the HFD control group after 4 weeks and
BIX supplemented groups.While in contrast, TNF-awas increased
by 29.0% (P < 0.05).Table 5 shows the effects of BIX-supplementation on the
liver lipogenic enzymes (G6PD, FAS, ME and PAP activities).
The consumption of BIX at a dose of 10 mg/kg led to an
important (P < 0.05) reduction of G6PD, FAS, ME, and PAP
activities (19.28%, 57.05%, 31.46% and 35.17% respectively) in
comparison with control group.
Table 5
Effect of supplementation with BIX on hepatic lipid regulating enzyme activities in C57BL/6J mice.
Groups (nmol/mg protein/min) Control HFD HFD + BIX-5 HFD + BIX-10 HFD + Orlistat
FAS 3.120 ± 0.039 1.560 ± 0.087a 1.340 ± 0.067a 3.010 ± 0.078
G6PD 1.970 ± 0.043 1.780 ± 0.071b 1.590 ± 0.043b 4.230 ± 0.540a
ME 69.340 ± 4.230 52.230 ± 3.770a 47.520 ± 4.840a 72.270 ± 5.190
PAP 870.130 ± 40.360 615.360 ± 43.820a 564.090 ± 29.730b 903.170 ± 52.650
Values are expressed as mean ± SEM. a: P < 0.05, b: P < 0.01, when compared to HFD group.
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in a concentration-related manner (IC50 value of 1.06 mg/mL)
which was higher than that achieved with orlistat (IC50 value of
0.02 mg/mL). The IC50 values of the a-amylase (34.24 mg/mL)
and a-glucosidase (1.48 mg/mL) inhibitory effects of BIX were
also higher than those presented by acarbose. BIX inhibited not
only pancreatic lipase but also a-amylase and a-glucosidase
activities.A B
DC
Table 6
Inhibitory effect of BIX on pancreatic lipase, a-amylase, a-glucosidase,
XO and LPO.
Group IC50 (mg/mL)
BIX Orlistat Acarbose
Lipase 1.06 ± 0.09 0.02 ± 0.06 –
a-Amylase 34.24 ± 5.17 – 0.48 ± 0.01
a-Glucosidase 1.48 ± 0.06 – 0.67 ± 0.00
XO 15.6 ± 2.45 – –
All values are expressed as mean ± SD (n = 3).Normal histological architecturewas seen in the pancreatic islet
of the control group (Figure 1A). Hydropic degeneration, shrunken
islets of Langerhans and lymphocyte inﬁltration were found in
untreated obese animals. The nucleus of the necrotic cells indicated
pyknosis or marginal hyperchromasia (Figure 1B). In the BIX
treatment groups, the cells of the islets of Langerhans appeared less
damaged, indicating that the cells were protected and suggesting
the strong anti-obesity potential of BIX (Figure 1C,D).A B
C D
Figure 1. Histological pictures of cellular population in the islets of
Langerhans in pancreas of mice.
A: Normal cellular population in the islets of Langerhans in pancreas of
vehicle-treated mice; B: Extensive damage to the islets of Langerhans
reduced dimensions of islets, and increased vacuolation; C and D: Resto-
ration of normal cellular population size of islets with hyperplasia by BIX.
Scale bar = 50 mm.Figure 2 shows the histological ﬁndings of liver sections. No
obese mice livers are presented in Figure 2A. Obese mice
without any treatment showed a cumulation of spherical vacu-
oles of fat droplets, variability in nuclear size, inﬂammatory cell
invasion, karyolysis and pyknosis (Figure 2B). These patho-
logical alterations were dramatically ameliorated in liver sec-
tions of obese mice treated with BIX where the sections showed
prominent nucleus and well-preserved cytoplasm, as well as
decreased hepatic steatosis more like normal hepatic structure
(Figure 2C,D). In addition, hyperlipidemic mice treated with
BIX showed hepatic lobules appearing in radiating plates of
strands of hepatocytes indicated a notable decrease of hepatocyte
fat droplets.Figure 2. Histological ﬁndings of liver sections.
A: Normal cellular population in the liver tissue of vehicle-treated mice; B:
HFD induced hepatic steatosis in mice; C and D: BIX supplementation
decreased accumulation of hepatic lipid droplets in HFD mice. Scale bar =
50 mm.4. Discussion
During the study period, BIX supplementation of obese mice
decreased adipose tissue mass with a reduction of body weight
without altering food intake. Measurements of the epididymal,
retroperitoneal and subcutaneous adipose tissue mass indicated
that BIX signiﬁcantly reverted adipose tissue masses accumu-
lation and adipocyte size increase compared to the HFD control
group. Also, BIX supplementation produces remarkable reduc-
tion of the body fat percentage, visceral fat weight and total fat.
ALT, AST GOT and GPT levels are biomarker enzymes used
to evaluate hepatic disturbance. The increase in the activities of
these enzymes in obese mice indicated hepatic damage. BIX
supplementation to hyperlipidemic mice produced remarkable
reduction in the activities of these enzymes indicating a
Rosa Martha Perez Gutierrez, Rita Valadez Romero/Asian Pac J Trop Biomed 2016; 6(12): 1015–10211020hepatoprotective effect; it also improved lipid proﬁles and
inhibited fat accumulation in the liver. Treatment with BIX
produced different degrees of protection to the liver and
pancreas which was conﬁrmed by the histologic and micro-
scopic study.
The reduction of serum total cholesterol, TG, LDL-C and
rise in HDL-C were observed in BIX treated obese mice, which
may be directly caused by an amelioration of insulin during
treatment or indirectly by the effect of BIX on lipid regulation
systems [18].
In obesemice,we found increased levels of TBARS, due toLPO
activation in tissues producing cellular inﬁltration and cell damage
[19]. In addition, we also found a decrease in the concentration
of antioxidant enzymes GSH, GSH-Px, SOD, CAT, and HO-1
which are essential to prevent the effect of ROS to cells.
The consumption of BIX at 10 mg/kg led to an important
(P < 0.05) reduction of TBARS levels and increased the con-
centrations of antioxidant enzymes compared to hyperlipidemic
untreated mice group. These results suggested that BIX pre-
vented oxidative stress. Given the importance of oxidative stress
in the development of obesity, XO inhibitors could be of sig-
niﬁcant therapeutic beneﬁt in obese patients.
Adipocytokine, leptin and adiponectin are secreted by adipose
tissue and are important in the regulation of metabolic and car-
diovascular homeostasis [20]. Leptin enhances fatty acid oxidation,
stimulates thermogenesis, decreases glucose level, inhibits appetite,
and food intake acting directly on the hypothalamus, thus reducing
body weight and fat. Levels of plasma leptin are signiﬁcantly
elevated in obese mice. Adiponectin reduces levels of tissue TG,
fatty acids content and increases tissue fat oxidation, which lead
to an improvement in the insulin sensitivity. Levels of plasma
adiponectin are signiﬁcantly diminished in obese mice. Treatment
with BIX produces a decrease of the level of plasmatic leptin in
obese mice. BIX supplementation produces a signiﬁcant weight
loss which elevates plasmatic adiponectin level and reduces leptin.
An additional mechanism for the hypolipidemic effect of
BIX is by reduction of G6PD, FAS, ME, and PAP activities.
However, BIX improves hypoglycemic effect due to a decreased
activity of the G6Pase probably by reducing homogentisate 1,2-
dioxygenase.
To further investigate the properties of BIX on reduction of
obesity risk, we examinated pancreatic lipase, a-glucosidase and
a-amylase inhibitory activities, because these enzymes are the
key enzymes in the digestion and absorption of lipids and car-
bohydrates [21]. a-Glucosidase and a-amylase reduce starch
hydrolysis as a mechanism to lower glucose. Inhibition of
pancreatic lipase is an important target for the treatment of
obesity. A marked inhibition of these enzymes was observed
after BIX administration.
In conclusion, the treatment with BIX in obese mice at two
different doses (5 mg/kg and 10 mg/kg) for 14 weeks reduced
visceral fat, suppressed body weight gain and plasma levels of
leptin, TG and total cholesterol and ALT, GPT, GOT, AST and
ALT activities compared with the high-fat-fed control mice. BIX
also elevated fecal lipid excretion, adiponectin level and antioxi-
dant enzymes GSH, GSH-Px, SOD, CAT, HO-1 and XO. In
addition, BIX decreased hepatic FAS, G6PD and PAP activities.
These results indicate that BIX has antioxidant and anti-visceral
obesity effects mediated by antioxidant metabolism and regula-
tion of lipid in obese mice. In addition, BIX shows hypoglycemic
effect which normalizes the glucose levels and improves insulin
resistance. Therefore, achiote which has a main component, thecarotenoid BIX could be a viable food for the treatment of obesity
and diabetes.
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